Revolution Medicines, Inc. (RVMD)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Revolution Medicines, Inc. reported revenue of $0. The company ran a net loss. It held $2.35B in total assets against $723.21M in total liabilities.
Key ratios (FY2025)
-69.3%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $11.58M | $35.38M | $29.39M | $42.98M | $50.04M | $20.16M | — |
| Operating Income | -$1.18B | -$689.52M | -$487.19M | -$258.28M | -$188.01M | -$110.70M | -$54.12M | -$40.33M | — |
| Net Income | -$1.13B | -$600.09M | -$436.37M | -$248.71M | -$187.09M | -$108.16M | -$47.66M | -$41.79M | — |
| EPS (Diluted) | $-5.95 | $-3.58 | $-3.86 | $-3.08 | $-2.57 | $-2.01 | — | — | — |
| Total Assets | $2.35B | $2.56B | $2.06B | $811.93M | $737.99M | $567.40M | $220.53M | — | — |
| Total Liabilities | $723.21M | $293.10M | $235.51M | $126.74M | $135.42M | $92.72M | $67.99M | — | — |
| Shareholders' Equity | $1.63B | $2.27B | $1.83B | $685.19M | $602.57M | $474.68M | -$152.57M | -$108.42M | -$67.72M |
| Cash & Equivalents | $383.75M | $543.06M | $696.15M | $161.41M | $108.50M | $104.27M | $16.66M | $69.59M | — |
| Operating Cash Flow | -$897.74M | -$557.44M | -$350.57M | -$224.40M | -$147.18M | -$100.06M | -$49.62M | $1.21M | — |
| Capital Expenditures | $15.99M | $10.31M | $7.73M | $10.82M | $6.53M | $2.93M | $2.59M | $1.50M | — |
| Shares Outstanding | 197.00M | 185.90M | 164.67M | 90.41M | 74.14M | 66.60M | 3.29M | — | — |